BUFFALO, NY- January 16, 2025 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 22 on December 2, 2024, entitled “Less frequent skin ulcers among patients with Werner syndrome treated with pioglitazone: findings from the Japanese Werner Syndrome Registry.”

The American Cancer Society (ACS) today released Cancer Statistics, 2025, the organization’s annual report on cancer facts and trends. The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting approximately 4.5 million deaths. However, this steady progress is jeopardized by increasing incidence for many cancer types, especially among women and younger adults, shifting the burden of disease. For example, incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002. This pattern includes lung cancer, which is now higher in women than in men among people younger than 65 years. These important findings are published today in CA: A Cancer Journal for Clinicians, alongside its consumer-friendly companion, Cancer Facts & Figures 2025, available on cancer.org.

A comprehensive review paper has brought new insights into the derivation of patient-derived organoids (PDOs) for cancer research, focusing on a comparative analysis of mechanical dissociation and enzymatic digestion techniques. It delves into how these methods influence key organoid properties such as stemness, heterogeneity, and their ability to be cultured long-term. The findings are instrumental in informing the selection of dissociation techniques based on tissue type and research objectives, with far-reaching implications for drug screening, cancer modeling, and the optimization of organoid production for more effective cancer research.

A recent study has made significant strides in uncovering how the oral microbiome, particularly the bacterium Fusobacterium nucleatum, plays a crucial role in the progression of oral squamous cell carcinoma (OSCC).

NCCN—an alliance of leading cancer centers—publishes a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

EPFL scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like hormones or drugs, opening up a world of possibilities in the computational design of molecular interactions for biomedicine.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The FDA ban on Red Dye 3, cancer survivorship and what it  means to live with cancer, global trends in lung cancer deaths, researching gynecologic cancer disparities in women of Arican ancestry and more are included in Sylvester Cancer's January tip sheet.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 

A new publication from Opto-Electronic Advances; DOI  10.29026/oea.2024.240105, discusses a high-resolution tumor marker detection based on microwave photonics demodulated dual wavelength fiber laser sensing system for the early screening of cancer.